North Capital Inc. Makes New $380,000 Investment in Edwards Lifesciences Corporation (NYSE:EW)

North Capital Inc. bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 5,244 shares of the medical research company’s stock, valued at approximately $380,000.

Other hedge funds also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $26,000. Vega Investment Solutions acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $27,000. Millstone Evans Group LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $29,000. Global X Japan Co. Ltd. lifted its stake in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after purchasing an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC raised its holdings in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after acquiring an additional 205 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the sale, the vice president owned 47,206 shares of the company’s stock, valued at $3,295,450.86. This trade represents a 16.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daveen Chopra sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the transaction, the vice president directly owned 33,496 shares of the company’s stock, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,648 shares of company stock valued at $2,998,866 over the last three months. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Down 0.2%

NYSE EW opened at $77.03 on Thursday. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average of $76.07 and a 200-day moving average of $73.24. The company has a market cap of $45.19 billion, a PE ratio of 11.00, a PEG ratio of 3.89 and a beta of 1.11. Edwards Lifesciences Corporation has a 12 month low of $58.93 and a 12 month high of $95.25.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the previous year, the firm posted $0.66 EPS. Edwards Lifesciences’s revenue was up 6.2% compared to the same quarter last year. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent analyst reports. Piper Sandler lifted their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, May 13th. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a “neutral” rating in a research report on Thursday, April 24th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Friday, May 16th. Dbs Bank upgraded shares of Edwards Lifesciences to a “hold” rating in a research report on Monday, June 2nd. Finally, Truist Financial cut their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $80.20.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.